does semaglutide cause heart issues in Cardiometabolic Diseases: SELECTing the Target Population Evaluating the Cardiovascular Benefits of

Note that this introduces a massive risk of user error

A specific example illustrating this progress is the November 2023 sanction granted by the US Food and Drug Administration to Eli Lilly and Company, an American pharmaceutical firm, for their product Zepbound, which is prescribed for ongoing weight control in adults struggling with obesity or excess weight complicated by conditions like type 2 diabetes or sleep apnea

or more than 2 but not more than 4 millimeters thick, without ulceration

PMID 6086881

Avoiding tight hairstyles that put traction on follicles (ponytails, braids, buns) removes another potential contributor to hair loss

3 In January 2026, the MHRA approved a higher dose of Wegovy, 7.2 mg, for adults with obesity (BMI of 30 or above)